Exact Sciences (EXAS) Cologuard outperforms Guardant Health's (GH) blood test in clinical trials
Exact Sciences Corporation (EXAS), is a molecular diagnostic company that specializes in developing and commercializing non-invasive screening tests for the early detection of various forms of cancer. The company's flagship product is Cologuard, a stool-based DNA screening test for colorectal cancer that was approved by the U.S. Food and Drug Administration (FDA) in 2014.
Since its initial public offering (IPO) in 2012, EXAS stock has experienced significant growth, with a compound annual growth rate (CAGR) of over 50% from 2012 to 2021. This growth can be attributed to the success of Cologuard and the company's expansion into other areas of cancer detection, including lung and pancreatic cancer.
In 2021, Exact Sciences announced that it had entered into a partnership with pharmaceutical giant Pfizer to develop and commercialize new cancer screening tests. This partnership, along with the increasing demand for non-invasive cancer screening options, has led to further optimism about the future growth potential of EXAS stock.
Despite its strong performance, EXAS stock is not without risk. The company is heavily reliant on the success of Cologuard, and any negative developments in the regulatory or competitive landscape could impact its financial performance. Additionally, the company has a significant amount of debt, which could become a burden if its growth slows or reverses.
Exact Sciences Corporation (EXAS) Recent Rise
Exact Sciences (EXAS) stock has risen following the news that Guardant Health's (GH) recent clinical trial for a colon cancer test did not perform as well as expected. The sensitivity of the test was 83%, which is lower than the 85% that the company had hoped for and significantly lower than the 92% sensitivity of Exact Sciences' rival test, Cologuard.
Despite the lower-than-expected results, Guardant Health intends to submit the test to the Food and Drug Administration (FDA) for commercial use. The news of Guardant Health's underperforming colon cancer test has been seen as a positive development for Exact Sciences, as it suggests that Cologuard may have a competitive advantage in the market. However, it is important to note that the success of any company's product is subject to various factors, including regulatory approval and market demand, and investors should carefully consider the risks before making any investment decisions.
The company's stock has reached a significant support level and has broken through the 200-day moving average, which is often seen as a long-term bullish trend indicator. This suggests that EXAS may be a good investment option for those looking to capitalize on positive market trends. You should subscribe today if you would like to know if EXAS is still in the AI stock prediction forecast.
AI Trading
Overall, EXAS stock has been a strong performer in recent years and has demonstrated significant potential for future growth. You can improve decision-making, outcome modeling and forecasting, and market information by combining big data analytics with our AI-powered stock prediction system. The main advantage of using AI for stock market analysis is that it can examine more assets objectively and continuously at all times of the day guiding you on how to make a profit even when the markets are as bearish as they are these days.
Our subscribers get exclusive market insights based on artificial intelligence and are updated daily about the best market opportunities before they happen.
Below is our stock pick from our 1 week stock forecast publicly announcing EXAS as a buy on Friday, December 9th, 2022. This stock pick has been available in multiple forecasts continuously over various time frames. As a subscriber, when you view your forecasts published daily, you can recognize better opportunities by looking for repetition of certain stock picks repeatedly remaining in the AI forecasts. Another indicator is when you see the stock pick appear in multiple forecasted time frames, especially over multiple forecasts published each morning EST.
The AI-powered stock market analysis computes the Signal Confidence (SC), which is expressed as a percentage out of 100%, based on the historical accuracy of each previous financial stock prediction, as well as current market factors relevant to stock pricing. The Signal Confidence (SC) in this stock forecast is 31%. When combined with machine learning, these incredibly intricate mathematical functions for statistical programming and modeling are capable of comparing their current coefficients and algorithms to newly added data and then adapting to improve the models' accuracy through a process of validation and reflection.
Stock Ticker | Open: Dec 9, 2022 | Close: Dec 16, 2022 | ROI% |
Exact Sciences Corporation (EXAS) | $45.70 | $51.92 | 13.61% |
Subscribers who bought EXAS stock based on our AI trading forecast for the 1-week time frame on Dec 9th, 2022 would have generated a significant short-term profit of 13.61% or $6.02 per share on this single trade. Discretion should always be used when analyzing the market. Your own due diligence is always required and you should always get advice from a licensed & certified financial counselor prior to implementing any financial plans.
Enhanced Market Intelligence
Finding market opportunities is made easier by using our AI system. It doesn't tell you what to do. It tells you where to look. Our skilled team of analysts carefully verifies the AI outputs and enhances this market research with a human touch, providing our subscribers with enhanced market intelligence. If you would like the AI advantage working for you, then you should subscribe today!
Life is better when you can be bullish.
Sources: 1. Investors Guardant Health, "Guardant Health announces positive results from pivotal ECLIPSE study evaluating a blood test for the detection of colorectal cancer" (2022)
Comments